ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,021.30
0.14%
US Tech 100
20,958.80
-0.40%
다우존스 지수
43,597.72
0.39%
Bitcoin
94,527.18
-1.81%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) 뉴스

Agenus Inc

Agenus Inc (AGEN)

NASDAQ
3.25
-0.07
( -2.11% )
업데이트: 01:50:16
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

AGEN 뉴스

공식 뉴스 전용

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
AGEN (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
AGEN (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
AGEN (-2.11%)

AGEN Discussion

게시물 보기
Monksdream Monksdream 2 월 전
AGEN under $3
👍️0
Monksdream Monksdream 4 월 전
AGEN under $5
👍️0
Monksdream Monksdream 6 월 전
AGEN new 52 week low
👍 1
Monksdream Monksdream 7 월 전
AGEN under $7
👍️0
ErnieBilco ErnieBilco 7 월 전
I tossed a couple of coins in the fountain at $7 wishing for 50% or better
👍️0
DP1011 DP1011 8 월 전
Up here. Keep on going!!!
👍️0
jondoeuk jondoeuk 10 월 전
I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.
👍️0
jondoeuk jondoeuk 11 월 전
The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.
👍️ 1
jondoeuk jondoeuk 11 월 전
They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html
👍️0
Paullee Paullee 1 년 전
where did you see that ??????
👍️0
TrendTrade2016 TrendTrade2016 1 년 전
ALL OUT...REVERSE SPLIT ANNOUNCEMENT
👍️0
TrendTrade2016 TrendTrade2016 1 년 전
AGEN SMALL GAPPER AND ON TARGET TO 1.04
👍️0
DP1011 DP1011 1 년 전
Interesting, would be nice to see this back over a dollar.
👍️0
Stumblebum Stumblebum 1 년 전
Something is cooking …..last week good upward movement and picked up volume 😊
👍️0
TrendTrade2016 TrendTrade2016 1 년 전
AGEN POPPING HARD TO 1.04
👍️0
axelvento axelvento 1 년 전
A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$
👍️0
Denzel-72 Denzel-72 1 년 전
R/S is coming … money down the drain
👍️0
Monksdream Monksdream 1 년 전
AGEN new 52 week low
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 1 년 전
$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 1 년 전
$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61
👍️0
Doktornolittle Doktornolittle 1 년 전
Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.
👍️0
Monksdream Monksdream 1 년 전
AGEN new 52 week low
👍️0
Monksdream Monksdream 1 년 전
AGEN new 52 week low
👍️0
Monksdream Monksdream 1 년 전
AGEN new 52 week low

👍️0
Monksdream Monksdream 1 년 전
AGEN new 52 week low
👍️0
Doktornolittle Doktornolittle 2 년 전
... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.
👍️0
Doktornolittle Doktornolittle 2 년 전
B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.
👍️0
Doktornolittle Doktornolittle 2 년 전
SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.
👍️ 1
stockguard stockguard 3 년 전
AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.
👍️0
north40000 north40000 3 년 전
$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.
👍️0
investtemp investtemp 3 년 전
what was the B Riley target price?
👍️0
stockguard stockguard 3 년 전
B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.
👍️0
stockguard stockguard 3 년 전
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html
👍️0
stockguard stockguard 3 년 전
Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s



👍️0
pipette pipette 3 년 전
There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.
👍️0
malice1 malice1 3 년 전
China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?
👍️0
Jnk Jnk 3 년 전
Got it!
👍️0
stockguard stockguard 3 년 전
Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.
👍️0
Jnk Jnk 3 년 전
Well I just bought a bunch more shares!! Hope it pays out!!
👍️0
stockguard stockguard 3 년 전
UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes
👍️0
stockguard stockguard 3 년 전
Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/
👍️0
malice1 malice1 3 년 전
longboarder have any idea what happened the last two days?
👍️0
longboarder7892 longboarder7892 3 년 전
Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.
👍️0
conix conix 4 년 전
AGEN Chart

👍️0
ClayTrader ClayTrader 4 년 전
* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
JohnLocke101 JohnLocke101 4 년 전
Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
👍️0
iancnyc iancnyc 4 년 전
thank god i heard on
look at that!!!
👍️0
moonurneighbor moonurneighbor 4 년 전
Great news!
👍️0
JohnLocke101 JohnLocke101 4 년 전
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
👍️0
iancnyc iancnyc 4 년 전
what’s going on with this Turd today?
👍️0

최근 히스토리

NASDAQ
AGEN
Agenus
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지